The purpose of the study is to determine whether Admilparant can be used safely over an extended period without causing serious side effects. Participants will take the medication each day and will attend regular visits where healthcare staff will check vital signs such as blood pressure and heart rate, review simple blood tests, and perform a basic heart test known as an ECG, which records the heart’s electrical activity. Any side effects that arise will be recorded and evaluated.

The study will continue for many months to gather enough information about safety and tolerability. Throughout the study, participants will be asked to report any new symptoms or problems, and they will receive routine medical check‑ups to monitor their overall health while using the medication.

The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

The main goal of the study is to see whether a single dose of the medicine is safe and whether it can raise protein levels to a normal range, with some participants receiving a second dose later to assess longer‑term effects. Participants will receive the infusion, then attend regular visits over several months during which blood samples and simple health checks are performed.

Researchers will watch for any side effects, measure the amount of the protective protein in the blood, and test how well it works using a laboratory test called a elastase inhibition assay. They will also check lung function and liver health through routine exams and questionnaires to understand how the treatment impacts overall well‑being.

Participants in the study will be randomly assigned to receive either cabozantinib plus supportive care or just supportive care. The study will monitor the participants over a period to see how the treatment affects the progression of the disease. The trial will also assess the safety of cabozantinib and how the body processes the drug, which is known as pharmacokinetics. The study will involve regular check-ups and assessments to track the health and progress of the participants.

The trial aims to provide valuable information on whether cabozantinib can help improve the outcomes for young people with osteosarcoma. The study will last for several months, and participants will be closely monitored throughout the process to ensure their safety and to gather data on the effectiveness of the treatment. The results of this study could potentially lead to better treatment options for those affected by this challenging condition.

Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations. The study will last for a period of time, during which participants will take the medication orally in the form of a modified-release tablet. The goal is to observe any changes in the severity of eczema symptoms and overall skin condition over the course of the study.

Throughout the study, participants will be monitored for any improvements in their eczema symptoms, such as reduced itching and inflammation, as well as any potential side effects. The study aims to provide valuable information on whether Upadacitinib can be an effective treatment option for those suffering from moderate to severe eczema. By participating in this study, researchers hope to gain insights that could lead to better management and treatment options for individuals with this challenging skin condition.

The purpose of the study is to see how well the combination treatment works compared to the single medication in preventing the return of melanoma after it has been surgically removed. Participants in the study will be randomly assigned to receive either the combination treatment or the single medication. Some participants may receive a placebo, which is a substance with no active medication. The study will last for up to 12 months, during which time participants will receive regular infusions and be monitored for any changes in their condition.

Throughout the study, researchers will keep track of how long participants remain free from melanoma returning, as well as other important health outcomes. These include how long participants live without the cancer spreading to other parts of the body, overall survival rates, and any side effects experienced. The study will also assess changes in participants’ quality of life and physical functioning. This information will help determine the effectiveness and safety of the combination treatment compared to the single medication.

The main goal of the trial is to learn how safe the medicine is and how well patients can tolerate increasing doses. Participants will receive the drug in a series of treatment cycles that last about four weeks each, with the amount of medicine gradually increased in early groups to find the highest dose that can be given without unacceptable side effects.

During the study, patients will have regular check‑ups, blood tests, and scans to watch for any side effects and to see how the cancer responds. Any problems that arise will be recorded and managed by the medical team, and the study will continue until the predetermined number of treatment cycles is completed or if a participant chooses to stop early.

Children in the study receive eye drops in a single-dose container and are followed over several months. During the study, eye health, vision, eye comfort, and possible side effects are checked at different visits and by phone calls. The study also looks at changes in the length of the eye, which can increase as myopia gets worse, as well as other eye findings such as redness, eye surface irritation, eye pressure, and the condition of the cornea, which is the clear front part of the eye.

The trial compares T10430 with placebo to learn more about safety and possible benefit. The treatment is given to both eyes, and the study follows participants for about one year.

The purpose of the study is to determine if niraparib can help patients live longer without the disease getting worse, compared to temozolomide. Participants in the study will be randomly assigned to receive either niraparib or temozolomide. The study will monitor the participants over time to see how the treatments affect their health and the progression of their glioblastoma.

Throughout the study, researchers will also look at how the treatments impact overall survival, which means the length of time patients live after starting the treatment. Additionally, the study will assess the participants’ symptoms, quality of life, and any side effects they may experience. This information will help determine the safety and effectiveness of niraparib compared to temozolomide for treating this specific type of glioblastoma.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

The purpose of the trial is to evaluate the safety and efficacy of the new combination therapy. Over a period of about four weeks, subjects will take the study medication once daily, while other participants receive a matching placebo. Safety will be monitored through reports of any side effects, regular blood tests, standard 12‑lead ECG recordings to check heart rhythm, and measurements of Sweat chloride levels, which reflect how the disease is affecting the body.

Effectiveness will be assessed by measuring lung function using the percent predicted forced expiratory volume in one second (ppFEV1) and by having participants complete a disease‑specific questionnaire that evaluates breathing symptoms (CFQ R). The study involves several clinic visits for these tests and for overall health checks.

The purpose of the study is to see whether adding GB-0895 can lower the number of serious asthma attacks over a one‑year period. Volunteers will receive the assigned injection at regular intervals for about 52 weeks and will attend routine visits where doctors will check lung function using simple breathing tests, ask about daily symptoms, and have participants fill out questionnaires that measure how asthma affects daily life and overall well‑being. Terms such as “subcutaneous” mean the medication is delivered under the skin, and “systemic corticosteroids” refer to steroid medicines taken by mouth or injection that help reduce inflammation during severe attacks.

After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.

The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

The study will test a medication called cemiplimab (also known as LIBTAYO), which is given through an intravenous infusion. This medicine belongs to a group of drugs called immunotherapy, which helps the body’s immune system fight cancer cells. The purpose is to determine if giving cemiplimab after surgery can help prevent the cancer from returning, compared to patients who receive no additional treatment after surgery.

During the study, participants will either receive cemiplimab treatment or be observed without treatment. The medication will be given through an infusion into a vein every few weeks. The total treatment period may last up to 42 weeks. Doctors will monitor the participants’ health and check if the cancer returns during and after the treatment period.

The purpose of the study is to compare the effectiveness of a new medicine with that of standard chemotherapy. The investigational drug being tested is Sofetabart Mipitecan (LY4170156). For participants with platinum-resistant disease, the new drug may be given alone and compared with the doctor’s choice of chemotherapy drugs such as carboplatin, paclitaxel, gemcitabine, topotecan or doxorubicin, or with Mirvetuximab Soravtansine. For those with platinum-sensitive disease, the new drug is combined with bevacizumab and compared with a standard platinum‑based two‑drug chemotherapy regimen plus bevacizumab.

Participants receive the study medicines through an IV infusion every few weeks and attend regular clinic visits where doctors perform physical examinations and imaging scans to check how the cancer is responding. Treatment continues until the cancer grows, side effects become unacceptable, or the study period ends, which may be several months for each participant.